Policies
Open Access Policy
European Journal of Rheumatology is an open access publication.
Starting on December 2018, all content published in the journal is licensed under the Creative Commons Attribution-NonCommercial (CC BY-NC) 4.0 International License which allows third parties to use the content for non-commercial purposes as long as they give credit to the original work. This license allows for the content to be shared and adapted for non-commercial purposes, promoting the dissemination and use of the research published in the journal.
The content published before December 2018 was licensed under a traditional copyright, but the archive is still available for free access.
All published content is available online, free of charge at https://www.eurjrheumatol.org/.
Authors retain unrestricted copyrights and publishing rights in the European Journal of Rheumatology.
Copyright Policy
A Copyright Agreement and Acknowledgement of Authorship form should be submitted with all manuscripts. By signing this form, authors agree that the article, if accepted for publication by the European Journal of Rheumatology, will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC 4.0) which permits third parties to share and adapt the content for non-commercial purposes by giving the appropriate credit to the original work.
When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial and criminal liabilities in this regard belong to the author(s).
Authors retain the copyright of their published work in the European Journal of Rheumatology.
Self-Archiving Policy
Authors retain the right to self-archive their work on their institutional or personal websites, as well as in open access repositories, after publication. It is expected that authors appropriately acknowledge the original publication and include the DOI number when sharing their articles. Additionally, authors are requested to provide a link from the deposited version to the URL of the publisher's website. This requirement is intended to safeguard the integrity and authenticity of the scientific record, with the online published version on the publisher's website clearly identified as the definitive version of record.
Publication Fee Policy
Starting January 24, 2025, European Journal of Rheumatology will implement an article processing charge (APC) for all articles.
Upon acceptance of a manuscript, authors are required to transfer the APC payment to the account specified in the acceptance letter. After the payment is made, please send the payment receipt to eurjrheum@avespublishing.com.
• Research Article/Review: 1950 USD + 3% Transaction Fee (59 USD) = 2009 USD
• Letter to the Editor: 1170 USD + 3% Transaction Fee (35 USD) = 1205 USD
• Case Report: 1170 USD + 3% Transaction Fee (35 USD) = 1205 USD
• Images in Rheumatology: 780 USD + 3% Transaction Fee (23 USD) = 803 USD
There are no additional fees or surcharges for the evaluation or publication process beyond the APC. For manuscripts submitted and accepted before January 24, 2025, the APC will be waived.
Any financial contribution or support received from third parties for a manuscript must be disclosed at the time of initial submission. If the APC is paid by a third party (other than the author or the author's institution), this information must be included on the title page and the ICMJE Disclosure Form.
APCs cover the costs associated with the publishing services the journal provides, including peer review management, professional production of articles in PDF and other formats, dissemination of published papers across various platforms, and other publishing functions.
We kindly request that authors whose manuscripts are accepted complete the APC payment within 90 days. Please note that publication will be on hold until payment is received. If the payment is not made within this period, the manuscript will be considered withdrawn. This policy helps ensure a timely and efficient publication process.
Waiver Policy
European Journal of Rheumatology offers 100% waivers on manuscripts whose submitting authors are based in countries classified by the World Bank as low-income economies.
Advertising Policy
European Journal of Rheumatology accepts digital advertisements on its website. These ads must be approved by the journal's Editorial Board and management and must be clearly labeled as advertisements. Advertisers have no influence on editorial decisions or advertising policies.
Those interested in advertising in the journal should contact the Editorial Office.
Peer Review Process
Manuscripts submitted to the European Journal of Rheumatology will go through a single anonymized peer-review process where the names of the reviewers are hidden from the author. Each submission will be reviewed by at least two external, independent peer reviewers who are experts in their fields in order to ensure an unbiased evaluation process.
Submissions will first go through a technical evaluation process during which the editorial office staff will ensure that the manuscript was prepared and submitted in accordance with the journal’s guidelines. Submissions that do not conform to the journal’s guidelines will be returned to the submitting authors with technical correction requests.
Submissions that conform to the journal’s guidelines will be assigned to the Editor in Chief who will assess each submission’s suitability to the journal in terms of scope and quality. Submissions that are not suitable for the journal can be rejected at this stage.
For papers that are suitable for the journal, the Editor in Chief will work with Associate Editors who will recruit reviewers for the manuscript. Once assigned, Associate Editors can decide to reject a manuscript, continue with the peer review process, or request revisions before further peer-review.
Associate editors will submit their recommendations that are based on reports submitted by the reviewers to the Editor in Chief. Revised manuscripts will be reassessed by the Associate Editors who will aim to work with the original reviewers to make a new recommendation.
The Editor in Chief is the final authority in the decision-making process for all submissions.
In the event of delays, authors will be informed of the reason for the delay and given the opportunity to withdraw their manuscript.
Once the peer-review process is completed, the authors will receive anonymous peer-review reports along with the editorial decision on their manuscript. Peer-review reports will not be posted publicly in any medium. The submitted material is considered confidential and must not be used in any way until after its publication. If it is suspected that a reviewer has appropriated an author’s ideas or data, the Editorial Board will handle the matter in accordance with the relevant COPE’s guideline.
Authors can recommend peer-reviewers during submission. The handling editor is the sole authority to decide whether or not recommended peer-reviewers will be invited to evaluate the manuscript.
Peer reviewers are required to adhere to the principles of COPE's Ethical Guidelines for Peer-reviewers and These guidelines provide a framework for reviewers to follow in order to ensure the integrity and fairness of the peer review process. The Editorial Board follows COPE’s relevant flowchart to minimize peer review manipulation. If there is suspicion of peer review manipulation after publication, the Editorial Board will follow the appropriate flowchart of COPE.
Potential peer reviewers should inform the Editor of any possible conflicts of interest before accepting an invitation to review a manuscript. Informing the editor of any potential conflicts of interest allows them to make an informed decision about whether or not to invite the potential reviewer to participate in the review process. It also helps to ensure the integrity and transparency of the review process.
Communications between Editors and peer reviewers contain confidential information that should not be shared with third parties.
To ensure an equitable peer-review process, the European Journal of Rheumatology will recruit external editors for manuscripts submitted by the Journal’s editorial board members. External editors will be selected based on academic qualifications and peer-review experience. We uphold the confidentiality of external editors and reviewers to preserve impartiality. Reviewers and external editors are asked to disclose any potential conflicts of interest, promoting transparency and a reliable evaluation process.
If an article's peer review is an exception to the journal’s usual policy, the type of the review it received will be displayed on the article to ensure the transparency and accountability of the review process.
Revisions
Submitting authors of manuscripts that require a “minor revision” or a “major revision” will receive the decision letter from the Editor in Chief. The decision letter will include the suggestions of the reviewers and editors along with a deadline to submit the revised and updated version of the manuscript.
When submitting a revised version of a paper, authors must submit a detailed “Response to the reviewers” that states point by point how each issue raised by the reviewers has been covered and where it can be found (each reviewer’s comment, followed by the author’s reply and line numbers where the changes have been made) as well as an annotated copy of the main document.
Revised manuscripts must be submitted within the time frame specified in the decision letter. If the revised version of the manuscript is not submitted within the allocated time, the revision option may be canceled. If the submitting author(s) believe that additional time is required, they should request an extension before the initial period is over.
Authorship
All individuals listed as an author should meet the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship is based on the following four criteria:
1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work.
2. Drafting the work or revising it critically for important intellectual content.
3. Final approval of the version to be published.
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
In addition to being accountable for the parts of the work they have done, authors should also be able to identify which co-authors are responsible for specific other parts of the work to ensure that the contributions of all authors are accurately and appropriately acknowledged. Authors may use CRediT (Contributor Roles Taxonomy) to provide information about individual contributions at the time of submission. It is expected that all authors agreed upon their individual contributions as shared by the corresponding author. The authors’ contribution statement will be published with the final article and should accurately reflect contributions to the work.
Furthermore, authors should have confidence in the integrity of the contributions of their co-authors. This means that they should trust that their co-authors have conducted the research in an ethical and responsible manner, and that the data and results presented in the manuscript are accurate and reliable.
Individuals who do not meet all four of the authorship criteria should not be included as authors on the manuscript. However, they can still be acknowledged on the title page of the manuscript for their contributions to the research in order to recognize the contributions of these individuals and to provide transparency about who was involved in the research.
If the editorial board suspects a case of ghost, honorary or gift authorship, the submission will be suspended and the <a href="https://publicationethics.org/resources/flowcharts/ghost-guest-gift-authorship-submitted-manuscript